Dupuytren’s disease cords are weakened ex vivo by injection of recombinant collagenase G – A proof-of-concept study

Guy Rubin, David Rothem, Ran Tohar, Maayan Gal · 2026

Read Dupuytren’s disease cords are weakened ex vivo by injection of recombinant collagenase G – A proof-of-concept study by Guy Rubin, David Rothem, Ran Tohar, Maayan Gal (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0359330.txt.

Description

Guy Rubin and three colleagues report a small laboratory test of a new enzyme treatment for Dupuytren's disease, published in PLOS ONE in 2026. The disease builds collagen rich cords in the hand that slowly pull fingers into a bent position. An injected bacteria made collagenase already treats it without surgery, and the team asked whether a lab made version of a related enzyme could do the same job.

They took cords removed during surgery from five patients, injected the test enzyme or a plain buffer, and pulled the tissue apart on a measuring machine. Enzyme treated cords tore under clearly less force, roughly a third lower in this tiny series. The authors call it early proof of concept and say dose, timing, and safety work must come before any patient use.

Catalog record

CREATORGuy Rubin, David Rothem, Ran Tohar, Maayan Gal
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE18301
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0359330

Browse the full library · About the Tower of Babel